Biomarkers for immunotherapy response: Paving the way towards personalized cancer treatment.

Rich Yard*

Department of Neurology, Columbia University, New York, USA

Introduction

In recent years, the landscape of cancer treatment has undergone a revolutionary transformation with the emergence of immunotherapy. Unlike conventional treatments that directly target cancer cells, immunotherapy harnesses the power of the immune system to combat tumors. While immunotherapy has demonstrated remarkable successes, not all patients respond equally to these treatments. This is where the concept of biomarkers for immunotherapy response comes into play. Biomarkers, measurable indicators of biological processes, offer a promising avenue to predict patient responses and tailor immunotherapy regimens for optimal outcomes [1].

Immunotherapy has heralded a new era in cancer treatment, with therapies such as immune checkpoint inhibitors, adoptive T-cell therapy, and cancer vaccines showing unprecedented efficacy. However, a significant challenge lies in identifying patients who are most likely to benefit from these treatments. Biomarkers serve as crucial tools in this endeavor, helping oncologists make informed decisions about treatment selection and avoiding unnecessary exposure to potentially ineffective therapies [2].

Biomarkers for immunotherapy response can be broadly classified into different categories based on the biological information they provide

Predictive biomarkers: These biomarkers help predict whether a patient is likely to respond positively to immunotherapy. For example, the expression levels of Programmed Death-Ligand 1 (PD-L1) on tumor cells have been associated with better responses to immune checkpoint inhibitors.

Prognostic biomarkers: Prognostic biomarkers offer insights into the patient's overall prognosis and disease outcome, irrespective of treatment. Their identification can aid in selecting appropriate patients for aggressive treatments [3].

Pharmacodynamic biomarkers: These biomarkers indicate the biological effects of immunotherapy on the tumor and immune microenvironment. Changes in the composition of immune cells within the tumor, like increased infiltration of cytotoxic T cells, can serve as pharmacodynamic biomarkers.

Mechanism-based biomarkers: These biomarkers provide information about specific mechanisms driving immunotherapy response or resistance. For example, the presence of tumor-infiltrating lymphocytes (TILs) may indicate a favorable response to immunotherapy.

Emerging biomarkers: Recent advances in genomics and molecular profiling have led to the discovery of novel biomarkers that hold promise in guiding immunotherapy decisions [4].

Tumor Mutational Burden (TMB): TMB reflects the number of genetic mutations within a tumor. Tumors with higher TMB tend to produce more neoantigens, increasing the chances of recognition by the immune system. Patients with high TMB have shown better responses to immune checkpoint inhibitors.

Microsatellite Instability (MSI): MSI is a result of DNA mismatch repair deficiency. Tumors with MSI tend to accumulate mutations, making them more immunogenic. Immunotherapies have demonstrated exceptional responses in patients with MSI-high tumors.

Challenges and future directions: While the potential of biomarkers for immunotherapy response is undeniable, several challenges remain. Biomarker validation across diverse patient populations, standardization of testing methodologies, and the dynamic nature of the tumor microenvironment all pose hurdles [5].

Conclusion

Biomarkers for immunotherapy response represent a crucial step towards achieving personalized cancer treatment. By unraveling the intricate relationship between the immune system and tumors, biomarkers empower clinicians to make informed decisions, increase treatment efficacy, and minimize adverse effects. As research advances, the integration of biomarkers into clinical practice holds the potential to transform the oncology field and bring us closer to the vision of tailored, patient-centered immunotherapy.

References

1. Gavrielatou N, Doumas S, Economopoulou P, et al. Biomarkers for immunotherapy response in head and neck cancer. Cancer Treat Rev. 2020;84:101977.
2. Spencer KR, Wang J, Silk AW, et al. Biomarkers for immunotherapy: current developments and challenges. Am Soc Clin Oncol Educ Boo. 2016;36:e493-503.

***Correspondence to:** Rich Yard, Department of Neurology, Columbia University, New York, USA E-mail: yard@columbia.edu

***Received:** 01-Aug-2023, Manuscript No. AACIR-23-112085; **Editor assigned:** 03-Aug-2023, Pre QC No. AACIR-23-112085(PQ); **Reviewed:** 17-Aug-2023, QC No. AACIR-23-112085; **Revised:** 21-Aug-2023, Manuscript No. AACIR-23-112085(R); **Published:** 28-Aug-2023, DOI: 10.35841/aacir-6.4.156*

***Citation:** Yard R. Biomarkers for immunotherapy response: Paving the way towards personalized cancer treatment. 2023;6(4): 156*

3. Duffy MJ, Crown J. Biomarkers for predicting response to immunotherapy with immune checkpoint inhibitors in cancer patients. Clin Chem. 2019;65(10):1228-38.

4. Larimer BM, Wehrenberg-Klee E, Dubois F, et al. Granzyme B PET imaging as a predictive biomarker of immunotherapy response. Cancer Res. 2017;77(9):2318-27.

5. Langouo Fontsa M, Padonou F, Willard-Gallo K. Biomarkers and immunotherapy: where are we?. Curr Opin Oncol. 2022;34(5):579-86.

Citation: *Yard R. Biomarkers for immunotherapy response: Paving the way towards personalized cancer treatment. 2023;6(4): 156*